Virax Biolabs Group Limited (NASDAQ:VRAX) Short Interest Update

Virax Biolabs Group Limited (NASDAQ:VRAX) was the target of a significant growth in short interest during the month of January. As of January 15th, there was short interest totalling 164,900 shares, a growth of 85.5% from the December 31st total of 88,900 shares. Currently, 4.1% of the shares of the stock are sold short. Based on an average daily trading volume, of 1,790,000 shares, the days-to-cover ratio is presently 0.1 days.

Virax Biolabs Group Stock Down 13.0 %

NASDAQ:VRAX traded down $0.25 during mid-day trading on Thursday, reaching $1.67. 349,665 shares of the company were exchanged, compared to its average volume of 387,443. Virax Biolabs Group has a 12 month low of $0.60 and a 12 month high of $9.00. The company has a fifty day moving average of $2.04 and a 200 day moving average of $2.20.

Virax Biolabs Group Company Profile

Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name.